Drug Profile
Research programme: diacylglycerol-O-acyltransferase inhibitors - Viking Therapeutics
Alternative Names: Enterocyte-directed DGAT-1 inhibitor program - Viking TherapeuticsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Viking Therapeutics
- Class
- Mechanism of Action Diacylglycerol O acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Dyslipidaemias in USA (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA